AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SOLSTICE MINERALS LTD

2.080

+0.0301.46%

Volume:192.82K

Turnover:410.74K

Market Cap:357.93M

PE:-59.03

High:2.170

Open:2.150

Low:2.080

Close:2.050

52wk High:2.500

52wk Low:0.270

Shares:172.08M

Float Shares:142.75M

Volume Ratio:6.63

T/O Rate:0.14%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.035

EPS(LYR):-0.030

ROE:-19.97%

ROA:-13.92%

PB:19.24

PE(LYR):-68.51

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Is SELLAS Life Sciences Group (SLS) Overvalued As Trial Milestones And Takeover Changes Stir Questions?

Simply Wall St.

Is Uncertain Galinpepimut-S Data Timing Reshaping SELLAS Life Sciences Group’s (SLS) Strategic Story?

Simply Wall St.

Solstice Minerals Extends Mineralization at Western Australia Copper-Gold Project Following Step-Down Diamond Tail Results, Shares Up 5%

MT Newswires Live

Are SELLAS Life Sciences (SLS) Loss Trends Masking a Shifting Cancer Vaccine Investment Narrative?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au.etasphere.com/stock/SLS.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"SLS.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SLS.AU\",,,,,undefined,":{"symbol":"SLS.AU","market":"AU","secType":"STK","nameCN":"SOLSTICE MINERALS LTD","latestPrice":2.08,"timestamp":1788134944001,"preClose":2.05,"halted":0,"volume":192824,"delay":0,"changeRate":0.014634146341463537,"nameEN":"SOLSTICE MINERALS LTD","floatShares":142749097,"shares":172083900,"eps":-0.035239,"marketStatus":"Trading","change":0.03,"latestTime":"08-31 10:09:16 AEST","open":2.15,"high":2.17,"low":2.08,"amount":410743,"amplitude":0.043902,"askPrice":2.09,"askSize":843,"bidPrice":2.08,"bidSize":570,"shortable":3,"etf":0,"ttmEps":-0.035239,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788156000000},"marketStatusCode":2,"adr":0,"listingDate":1651327200000,"exchange":"ASX","adjPreClose":2.05,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":6.629154,"lotSize":0,"tradeCurrency":"AUD","auctionPricing":{"symbol":"SLS.AU","preClose":2.05,"auctionPrice":2.15,"auctionVolume":17050,"auctionTime":1788134341551,"referenceTime":1787913003093,"auction":1,"marketStatus":"盘前竞价","timestamp":1788134341551}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SLS.AU\",,,,,undefined,":{"symbol":"SLS.AU","floatShares":142749097,"roa":"-13.92%","roe":"-19.97%","lyrEps":-0.030362,"volumeRatio":6.629154,"shares":172083900,"dividePrice":0,"high":2.17,"amplitude":0.043902,"preClose":2.05,"low":2.08,"week52Low":0.27,"pbRate":"19.24","week52High":2.5,"institutionHeld":0,"latestPrice":2.08,"committee":-0.193206,"eps":-0.035239,"divideRate":0,"volume":192824,"delay":0,"ttmEps":-0.035239,"open":2.15,"prevYearClose":0.41,"prevWeekClose":2.05,"prevMonthClose":2.16,"prevQuarterClose":2.37,"fiveDayClose":1.81,"twentyDayClose":2.15,"sixtyDayClose":1.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLS.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLS.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLS.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663047870","title":"Is SELLAS Life Sciences Group (SLS) Overvalued As Trial Milestones And Takeover Changes Stir Questions?","url":"https://stock-news.laohu8.com/highlight/detail?id=2663047870","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663047870?lang=en_us&edition=fundamental","pubTime":"2026-08-31 01:20","pubTimestamp":1788110406,"startTime":"0","endTime":"0","summary":"Trial Milestone and Executive Changes Put SELLAS Life Sciences Group Stock in Focus\nSELLAS Life Sciences Group (SLS) drew attention after a report indicated its phase 3 trial for acute myeloid leukemia reached the 80th patient death, a key trigger for Galinpepimut S results.\nThe company has not commented on this reported milestone. Recent amendments to executive employment agreements that add takeover related benefits have prompted investors to reassess what might be next for the stock.\nAt a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/is-sellas-life-sciences-group-sls-overvalued-as-trial-milest","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/is-sellas-life-sciences-group-sls-overvalued-as-trial-milest","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLS","BK7104","BK4139","SLS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663177050","title":"Is Uncertain Galinpepimut-S Data Timing Reshaping SELLAS Life Sciences Group’s (SLS) Strategic Story?","url":"https://stock-news.laohu8.com/highlight/detail?id=2663177050","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663177050?lang=en_us&edition=fundamental","pubTime":"2026-08-29 23:21","pubTimestamp":1788016865,"startTime":"0","endTime":"0","summary":"Earlier this year, SELLAS Life Sciences Group came under scrutiny after reports that its phase 3 acute myeloid leukemia trial for Galinpepimut-S had reached a key mortality-related milestone without a corresponding company update.\nInvestor attention has also focused on recently amended executive employment agreements that include enhanced benefits in the event of a takeover, raising questions about potential corporate actions alongside the unresolved trial outcome.\nWe’ll now explore how the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/is-uncertain-galinpepimut-s-data-timing-reshaping-sellas-lif","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/is-uncertain-galinpepimut-s-data-timing-reshaping-sellas-lif","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7104","BK4139","SLS.AU","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662713058","title":"Solstice Minerals Extends Mineralization at Western Australia Copper-Gold Project Following Step-Down Diamond Tail Results, Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662713058","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662713058?lang=en_us&edition=fundamental","pubTime":"2026-08-28 11:06","pubTimestamp":1787886402,"startTime":"0","endTime":"0","summary":"Solstice Minerals  said results from a step-down diamond tail from a drill hole at the Nanadie copper-gold project in Western Australia extended mineralization more than 700 meters below the surface, according to a Friday Australian bourse filing.It encountered a total combined intercept of 722.3 meters at 0.44% copper and 0.13 grams per tonne grade of gold from the margin of granite to the end of the hole, including an intercept of 43.3 meters at 0.91% copper and 0.35 g/t grade of gold from 761.7 meters.The diamond tail was drilled from 324.3 meters to a final depth of 840.6 meters, extending a phase one reverse circulation drill hole.The firm's shares rose 5% in recent trading on Friday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UYM","E200.AU","IMLC.AU","QFN.AU","BK4588","BEAR.AU","QRE.AU","EIGA.AU","VAS.AU","WRN","XJO.AU","GIVE.AU","STW.AU","OZR.AU","DACE.AU","IIGF.AU","IISV.AU","SETM","XKO.AU","COPX","IOZ.AU","BBOZ.AU","XAO.AU","PICK","SLS.AU","VAP.AU","OZF.AU","BK4535","BK4585","BK4168","XME","DBB","GEAR.AU","MTX","BK4109","BK7104","SLF.AU","ZYAU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661521680","title":"Are SELLAS Life Sciences (SLS) Loss Trends Masking a Shifting Cancer Vaccine Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2661521680","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661521680?lang=en_us&edition=fundamental","pubTime":"2026-08-22 12:35","pubTimestamp":1787373335,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group, Inc. reported second-quarter 2026 results, with net loss rising to US$9.61 million from US$6.60 million a year earlier, while basic loss per share from continuing operations narrowed to US$0.05 from US$0.07.\nFor the first half of 2026, the company’s net loss increased to US$18.01 million from US$12.41 million, yet basic loss per share improved to US$0.10 from US$0.13, as investor attention was also drawn to renewed interest in immune-based cancer therapies...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/are-sellas-life-sciences-sls-loss-trends-masking-a-shifting","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/are-sellas-life-sciences-sls-loss-trends-masking-a-shifting","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLS.AU","BK4139","SLS","BK7104"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":10,"pageCount":1,"totalSize":37,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/SLS.AU\",params:#limit:6,delay:true,,,undefined,":[]}}